Raymond James Financial
PPBT

Raymond James Financial’s Purple Biotech PPBT Stock Holding History

Raymond James Financial’s Portfolio PPBT Stock Details PPBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-56
Closed -$1.3K – 6286
2025
Q2 		$1.3K Buy
+56
New +$1.38K ﹤0.01% 6514

Other funds holding PPBT

VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
TCM
Tradewinds Capital Management Bellingham, Washington $563M AUM 41.52% 1-Year Est. Return
ASN
Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return
Northwestern Mutual Wealth Management
Northwestern Mutual Wealth Management Milwaukee, Wisconsin $162B AUM 16.35% 1-Year Est. Return

Raymond James Financial's PPBT Position: Q3 2025 in Review

Raymond James Financial sold out of Purple Biotech (PPBT) in Q3 2025, closing a stake of 56 shares — an estimated $1.3K sold.

Raymond James Financial first reported a position in PPBT in Q2 2025 and held it in 1 quarter. The position peaked at $1.3K in Q2 2025. 16 funds tracked by Wall St. Rank hold PPBT as of Q3 2025.

  • Raymond James Financial reported no remaining Purple Biotech position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 56 Purple Biotech shares in Q3 2025, an estimated $1.3K.
  • Raymond James Financial first reported a position in Purple Biotech in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Purple Biotech position peaked at $1.3K in Q2 2025.
  • 16 funds tracked by Wall St. Rank held Purple Biotech as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.